Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001104659-25-045628·Liminatus Pharma, Inc.
Schedule 13D ownership disclosure
LIMINATUS PHARMA INC.
Common Stock · CUSIP: 53271X108
Event date: 2025-04-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Valetudo Therapeutics LLCReported CIK 0002067359
Shares: 6,169,406.00 · Class: 23.7%
- Chris KimReported CIK 0001972385
Shares: 6,169,406.00 · Class: 23.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-045628
- Form type
- SCHEDULE 13D
- Filer
- Liminatus Pharma, Inc.
- CIK
- CIK 1971387
- Filed
- May 07, 2025
- Reporting period
- Apr 30, 2025
- Description
- Schedule 13D beneficial ownership